Condition: Diabetes Mellitus, Type 2 · PreDiabetes · Pancreas Cyst · Sponsor: University of Nebraska
Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.
This description comes directly from the study's public registry record.
Suzanne M Wessling, RN, BSN · 402-559-1577 · suzanne.wessling@unmc.edu
Kelsey A Klute, MD · 402-559-8500 · kelsey.klute@unmc.edu
Always discuss trial participation with your own doctor first.
| Unversity of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03568630